Limits...
Immunization with a live attenuated H7N9 influenza vaccine protects mice against lethal challenge.

Yang X, Zhao J, Wang C, Duan Y, Zhao Z, Chen R, Zhang L, Xing L, Lai C, Zhang S, Wang X, Yang P - PLoS ONE (2015)

Bottom Line: The emergence of severe cases of human influenza A (H7N9) viral infection in China in the spring of 2003 resulted in a global effort to rapidly develop an effective candidate vaccine.Intranasal immunization of female BALB/c mice with Ah01/AA ca twice at a 2-week interval induced robust humoral, mucosal, and cell-mediated immune responses in a dose-dependent manner.Taken together, these data support the further evaluation of this Ah01/AA ca candidate vaccine in primates.

View Article: PubMed Central - PubMed

Affiliation: Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China.

ABSTRACT
The emergence of severe cases of human influenza A (H7N9) viral infection in China in the spring of 2003 resulted in a global effort to rapidly develop an effective candidate vaccine. In this study, a cold-adapted (ca), live attenuated monovalent reassortant influenza H7N9 virus (Ah01/AA ca) was generated using reverse genetics that contained hemagglutinin (HA) and neuraminidase (NA) genes from a 2013 pandemic A H7N9 isolate, A/Anhui/01/2013 virus (Ah01/H7N9); the remaining six backbone genes derived from the cold-adapted influenza H2N2 A/Ann Arbor/6/60 virus (AA virus). Ah01/AA ca virus exhibited temperature sensitivity (ts), ca, and attenuation (att) phenotypes. Intranasal immunization of female BALB/c mice with Ah01/AA ca twice at a 2-week interval induced robust humoral, mucosal, and cell-mediated immune responses in a dose-dependent manner. Furthermore, the candidate Ah01/AA ca virus was immunogenic and offered partial or complete protection of mice against a lethal challenge by the live 2013 influenza A H7N9 (A/Anhui/01/2013). Protection was demonstrated by the inhibition of viral replication and the attenuation of histopathological changes in the challenged mouse lung. Taken together, these data support the further evaluation of this Ah01/AA ca candidate vaccine in primates.

Show MeSH

Related in: MedlinePlus

Production of an influenza Ah01/AA ca vaccine candidate using reverse genetics.The characteristics of Ah01/AA ca transfectant viruses were confirmed by visualizing the shape and size distribution of the virus particles. (A) Recombinant Ah01/AA ca virus particles were visualized using electron microscopy. (B) Ah01/AA ca virus particles were measured; 82% (out of 200 particles measured) ranged in size between 80 and 120 nm.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4401572&req=5

pone.0123659.g001: Production of an influenza Ah01/AA ca vaccine candidate using reverse genetics.The characteristics of Ah01/AA ca transfectant viruses were confirmed by visualizing the shape and size distribution of the virus particles. (A) Recombinant Ah01/AA ca virus particles were visualized using electron microscopy. (B) Ah01/AA ca virus particles were measured; 82% (out of 200 particles measured) ranged in size between 80 and 120 nm.

Mentions: The reassortant Ah01/AA ca viruses were produced through the use of reverse genetics. The infectious titers were 7.5–8.5 log10 CCID50/ml for the Ah01/AA ca. The reassortant Ah01/AA ca viral particles were examined by electron microscopy and exhibited spherical structures 80–120 nm in size and a typical lipid membrane bilayer on their outer surface (Fig 1A and 1B). Meanwhile, the HA and NA from Ah01/AA ca vaccine was fully sequenced and was identical as that of wt Ah01/H7N9 virus.


Immunization with a live attenuated H7N9 influenza vaccine protects mice against lethal challenge.

Yang X, Zhao J, Wang C, Duan Y, Zhao Z, Chen R, Zhang L, Xing L, Lai C, Zhang S, Wang X, Yang P - PLoS ONE (2015)

Production of an influenza Ah01/AA ca vaccine candidate using reverse genetics.The characteristics of Ah01/AA ca transfectant viruses were confirmed by visualizing the shape and size distribution of the virus particles. (A) Recombinant Ah01/AA ca virus particles were visualized using electron microscopy. (B) Ah01/AA ca virus particles were measured; 82% (out of 200 particles measured) ranged in size between 80 and 120 nm.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4401572&req=5

pone.0123659.g001: Production of an influenza Ah01/AA ca vaccine candidate using reverse genetics.The characteristics of Ah01/AA ca transfectant viruses were confirmed by visualizing the shape and size distribution of the virus particles. (A) Recombinant Ah01/AA ca virus particles were visualized using electron microscopy. (B) Ah01/AA ca virus particles were measured; 82% (out of 200 particles measured) ranged in size between 80 and 120 nm.
Mentions: The reassortant Ah01/AA ca viruses were produced through the use of reverse genetics. The infectious titers were 7.5–8.5 log10 CCID50/ml for the Ah01/AA ca. The reassortant Ah01/AA ca viral particles were examined by electron microscopy and exhibited spherical structures 80–120 nm in size and a typical lipid membrane bilayer on their outer surface (Fig 1A and 1B). Meanwhile, the HA and NA from Ah01/AA ca vaccine was fully sequenced and was identical as that of wt Ah01/H7N9 virus.

Bottom Line: The emergence of severe cases of human influenza A (H7N9) viral infection in China in the spring of 2003 resulted in a global effort to rapidly develop an effective candidate vaccine.Intranasal immunization of female BALB/c mice with Ah01/AA ca twice at a 2-week interval induced robust humoral, mucosal, and cell-mediated immune responses in a dose-dependent manner.Taken together, these data support the further evaluation of this Ah01/AA ca candidate vaccine in primates.

View Article: PubMed Central - PubMed

Affiliation: Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China.

ABSTRACT
The emergence of severe cases of human influenza A (H7N9) viral infection in China in the spring of 2003 resulted in a global effort to rapidly develop an effective candidate vaccine. In this study, a cold-adapted (ca), live attenuated monovalent reassortant influenza H7N9 virus (Ah01/AA ca) was generated using reverse genetics that contained hemagglutinin (HA) and neuraminidase (NA) genes from a 2013 pandemic A H7N9 isolate, A/Anhui/01/2013 virus (Ah01/H7N9); the remaining six backbone genes derived from the cold-adapted influenza H2N2 A/Ann Arbor/6/60 virus (AA virus). Ah01/AA ca virus exhibited temperature sensitivity (ts), ca, and attenuation (att) phenotypes. Intranasal immunization of female BALB/c mice with Ah01/AA ca twice at a 2-week interval induced robust humoral, mucosal, and cell-mediated immune responses in a dose-dependent manner. Furthermore, the candidate Ah01/AA ca virus was immunogenic and offered partial or complete protection of mice against a lethal challenge by the live 2013 influenza A H7N9 (A/Anhui/01/2013). Protection was demonstrated by the inhibition of viral replication and the attenuation of histopathological changes in the challenged mouse lung. Taken together, these data support the further evaluation of this Ah01/AA ca candidate vaccine in primates.

Show MeSH
Related in: MedlinePlus